MolecuLight Achieves Milestone with FIPS 140-3 Certification Enhancing Wound Imaging Security

MolecuLight Achieves FIPS 140-3 Validation for Its Wound Imaging Device

MolecuLight Corp. recently announced a significant achievement that enhances the security and reliability of its MolecuLightDX+ wound imaging device. The device's encryption module has received validation under the Federal Information Processing Standard (FIPS) 140-3. This milestone not only elevates the standing of the MolecuLightDX+ in the healthcare sector but also provides critical assurance to healthcare organizations regarding the safety of sensitive patient information.

The FIPS 140-3 is a standard mandated by the U.S. government to ensure that cryptographic modules used to safeguard sensitive information meet stringent security requirements. The validation process for the MolecuLightDX+ was conducted under the Cryptographic Module Validation Program (CMVP), culminating in the issuance of Certificate #5533 on September 28, 2026. This rigorous testing was performed by an accredited independent laboratory, confirming that the encryption module adheres to government-defined benchmarks.

Anil Amlani, CEO of MolecuLight, emphasized the importance of this development: “Healthcare organizations need confidence in both the clinical capabilities of their technology and the safeguards protecting patient information.” He reiterated that this validation reflects the company’s commitment to providing secure wound imaging solutions, thereby reinforcing trust with customers and stakeholders alike.

The validated encryption module is integrated across various configurations of the MolecuLightDX+, including standalone devices and packages that integrate with electronic medical records. This uniformity in encryption capabilities across diverse clinical settings enhances the overall data security framework for healthcare providers.

MolecuLight's advancement in achieving FIPS 140-3 validation not only establishes a benchmark for encryption security in their devices but also aligns with healthcare authorities' increasing demands for compliance with data protection regulations. For hospitals and healthcare systems, this validation serves as a crucial deciding factor when evaluating the security of medical technology.

Moreover, the capability of the MolecuLightDX+ extends beyond encryption; the device is designed to provide real-time detection of elevated bacterial burden and conducts precise digital wound measurement. These functionalities are supported by over 115 peer-reviewed publications that underline the clinical utility and effectiveness of the MolecuLight systems.

Healthcare providers are continually tasked with implementing technology that not just offers clinical efficacy but also adheres to security protocols that protect patient data. The accomplishment of FIPS 140-3 validation thus positions MolecuLight as a leader in ensuring that advanced medical imaging solutions also meet critical data security standards.

For more detailed information about the FIPS 140-3 validation and its implications for healthcare technology, interested parties can visit the NIST validation record.

In summary, MolecuLight's recent achievement marks a pivotal advancement in the intersection of medical imaging and data security, ultimately enhancing the safety and reliability of healthcare technology. As the medical field continues to evolve in its approach toward patient care and data management, innovations like MolecuLightDX+ serve as vital tools in facilitating this progress.